Want to see TSE:MOOD full AI Analyst Report?
Doseology Sciences (MOOD) Stock Statistics & Valuation Metrics
Total Valuation
Doseology Sciences has a market cap or net worth of CAD 680.99K. The enterprise value is CAD 6.33M.
- Market Cap
- CAD 680.99K
- Enterprise Value
- CAD 6.33M
Share Statistics
Doseology Sciences has 8,011,621 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,011,621
- Owned by Insiders
- 5.87%
- Owned by Institutions
- ―
Financial Efficiency
Doseology Sciences’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -33.74%.
- Return on Equity (ROE)
- -0.32
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -33.74%
- Return on Capital Employed (ROCE)
- -0.34
- Revenue Per Employee
- 8,511.2
- Profits Per Employee
- -89.56K
- Employee Count
- 5
- Asset Turnover
- 0.03
- Inventory Turnover
- 1.39
Valuation Ratios
The current PE Ratio of Doseology Sciences is -0.57. Doseology Sciences’s PEG ratio is 0.01.
- PE Ratio
- -0.57
- PS Ratio
- 8.38
- PB Ratio
- 0.94
- Price to FCF
- -6.69
- Price to Operating Cash Flow
- -10.18
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Doseology Sciences had revenue of 42.56K and earned -447.79K in profits. Earnings per share was -0.10.
- Revenue
- 42.56K
- Gross Profit
- 18.89K
- Operating Income
- -471.61K
- Pretax Income
- -447.79K
- Net Income
- -447.79K
- EBITDA
- -471.61K
- Earnings Per Share (EPS)
- -0.10
Cash Flow
In the last 12 months, operating cash flow was -230.85K and capital expenditures 0, giving a free cash flow of -230.84K billion.
- Operating Cash Flow
- -230.85K
- Free Cash Flow
- -230.84K
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Doseology Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.95%
- Earnings Yield
- -112.87%
Stock Price Statistics
- Beta
- -2.75
- 52-Week Price Change
- -71.67%
- 50-Day Moving Average
- 0.15
- 200-Day Moving Average
- 0.38
- Relative Strength Index (RSI)
- 32.59
- Average Volume (3m)
- 4,623
Important Dates
Doseology Sciences upcoming earnings date is Nov 26, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Nov 26, 2026
- Ex-Dividend Date
- ―
Financial Position
Doseology Sciences as a current ratio of 15.85, with Debt / Equity ratio of 0.00%
- Current Ratio
- 15.85
- Quick Ratio
- 15.67
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.03
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Doseology Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Doseology Sciences EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -3.08.
- EV to Sales
- 3.86
- EV to EBITDA
- -0.26
- EV to Free Cash Flow
- -3.08
- EV to Operating Cash Flow
- -3.08
Balance Sheet
Doseology Sciences has CAD 1.43M in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of CAD 1.43M billion.
- Cash & Marketable Securities
- CAD 1.43M
- Total Debt
- CAD 0.00
- Net Cash
- CAD 1.43M
- Net Cash Per Share
- CAD 0.18
- Tangible Book Value Per Share
- CAD 0.29
Margins
Gross margin is -517.35%, with operating margin of -1462.99%, and net profit margin of -1439.30%.
- Gross Margin
- -517.35%
- Operating Margin
- -1462.99%
- Pretax Margin
- -1439.30%
- Net Profit Margin
- -1439.30%
- EBITDA Margin
- -1462.99%
- EBIT Margin
- -1462.99%
Analyst Forecast
The average price target for Doseology Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 73.76%
- EPS Growth Forecast
- -108.30%
Scores
- Smart Score
- ―
- AI Score
- 42